Scienture Holdings, Inc. (SCNX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US80880X1046
Scienture Holdings, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 431,609.00 USD |
| Gross profit | 331,482.00 USD |
| Operating income | -42.59 m USD |
| EBIT | -39.42 m USD |
| Net income | -41.51 m USD |
| Diluted EPS – continuing operations | -2.70 USD |
Full history since 2005, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
More stocks
- Upland Software, Inc. (UPLD)
- AleeanPeace Group Holdings Ltd (APGH)
- ATIF Holdings Ltd (AUC)
- Luvu Brands, Inc. (LUVU)
- SciBase Holding AB (publ) (SCIB.ST)
- Skye Bioscience, Inc. (SKYE)
- BLUM HOLDINGS, INC. (BLMH)
- ATHENA GOLD CORP (AHNRF)
- Digerati Technologies, Inc. (DTGI)
- FOCUS UNIVERSAL INC. (FCUV)
- Scilex Holding Co (SCLX)
- Elme Communities (ELME)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.